Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genera Biosystems Ltd announces FDA advisory committee recommends HPV test as primary cervical cancer screening tool


Monday, 17 Mar 2014 12:00am EDT 

Genera Biosystems Ltd:Announces unanimous decision of the Microbiology Devices Panel of the Medical Devices Advisory Committee of the U.S. Food and Drug Administration (FDA).FDA Advisory Committee has decided that the benefits of using Roche‚Äôs cobas HPV (Human Papillomavirus) Test as a first line, primary screening tool.If approved, the cobas HPV Test would become the first HPV test indicated as the first-line primary screen of cervical cancer in the United States. 

Company Quote

0.24
-0.01 -4.00%
16 Sep 2014